The arrival of these anti PD-1/PD-L1 monoclonal antibodies has changed the first line of treatment of these patients with the possibility of using Pembrolizumab when tumor cells have a PD-L1 expression of at least 50% [8]. The gene discussed is CD274; the disease is neoplasm.